Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
April 26, 2025 10:00 ET | Source: Protara Therapeutics TARA-002 demonstrates 100%…
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
April 25, 2025 13:17 ET | Source: Pyxis Oncology Gene signatures associated…
Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 25, 2025 13:10 ET | Source: Starton Therapeutics Inc. PARAMUS, N.J.,…
Advantage Solutions Announces Date for its First Quarter 2025 Financial Results and Conference Call
April 25, 2025 11:30 ET | Source: Advantage Solutions, Inc. ST. LOUIS,…
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 24, 2025 17:00 ET | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif.,…
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
April 24, 2025 16:30 ET | Source: CVRx, Inc. MINNEAPOLIS, April 24,…
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
April 23, 2025 17:23 ET | Source: Mineralys Therapeutics, Inc. – Significant…
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
April 23, 2025 17:14 ET | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md.,…
Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results
April 23, 2025 17:01 ET | Source: Aurora Spine Corporation CARLSBAD, California,…
Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025
April 23, 2025 17:00 ET | Source: Jushi Holdings Inc. BOCA RATON,…